PDS BIOTECHNOLOGY CORP

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

20 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

15 Sep 2021 08:30:01 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 

13 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

09 Sep 2021 08:30:01 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

12 Aug 2021 07:05:00 By Nasdaq GlobeNewswire

PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences

28 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

26 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Joins Russell Microcap® Index

01 Jul 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

17 Jun 2021 16:15:10 By Nasdaq GlobeNewswire